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Objective: In this study, the results of the proteomic analysis of plasma samples of stable
angina patients are presented.
Background: Plasma samples from 44 patients were analysed in two groups: (A) a control
group of 22 patients without significant coronary artery disease and (B) 22 patients
admitted with stable angina pectoris.
Methods: During coronary angiography, plasma samples were collected and further
analysed using two-dimensional gel electrophoresis, image analysis and mass spectro-
metry.
Results: Five spots were found with significantly increased or decreased normalised
volumes resulting from either a change in the amount of protein or changes in
posttranslational modifications. Spots containing serum amyloid A protein and fibrinogen
gamma chains displayed increased normalised volumes, and spots containing apoliprotein
A-1 and pigment epithelium derived factor showed decreased normalised volumes.
Conclusions: Almost identical proteomic profiles of the stable angina pectoris group
compared with the control group corresponded well with clinical results comparing stable
patients with the general population.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All
rights reserved.1. Introduction
The development of genetic research to rapidly move from
bench to bedside is one of the most challenging fields for
clinically applied research. Molecular profiling technologies to
assess the occurrence, appearance and amounts of DNA,
RNA, protein and metabolites are the foundation for the
‘‘omics’’ disciplines (genomics, proteomics and metabolo-
mics). These disciplines provide the opportunity to poten-
tially strengthen the concept of ‘‘personalised medicine’’.
Genomics is utilising methods to identify genes and theirch Society of Cardiology.
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. Maly´)polymorphisms to compare the results with phenotypes and
vice versa. Different types of genetic studies are used for this
purpose [1,2]. Next, proteomic and metabolomicdisciplines
analyse the final results of genes—metabolites, proteins and
their posttranslational modifications. Progress in the search
for new therapeutic tools and potentially new biomarkers in
atherosclerosis has moved forward due to analysis of genes,
results of their expression and identification of proteins using
proteomic analysis [3]. We are presenting the results of
proteomic analysis of plasma samples from stable angina
pectoris patients.Published by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.
.
Table 3 – Classification and angiographic results of the
stable angina subgroup.
N (%)
CCS 1 4 (18)
CCS 2 12 (55)
CCS 3 6 (27)
1 VD 6 (27)
2 VD 9 (41)
3 VD 7 (32)
CCS—severity of angina according to the Canadian Cardiovascular
Society classification.
VD—number of vessel diseased.
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Plasma samples were collected from 44 patients in two
subgroups: (A) 22 patients without significant coronary artery
disease (controls) and (B) 22 patients with stable angina
pectoris (SAP) and significant coronary artery disease accord-
ing to angiography. The characteristics of the study groups
are summarised in Table 1. The reasons for coronary
angiography of the controls are summarised in Table 2.
Subgroup A is a heterogeneous population with the
common characteristic of the absence of significant coronary
artery disease during coronary angiography. Subgroup B
consists of the patients undergoing angiography due to SAP.
13 patients had the history of typical chest pain during
exertion and established ischaemic heart disease with known
coronary artery disease, and 9 patients had history of typical
chest pain and newly diagnosed significant coronary artery
disease on the coronary angiography. The classification of the
SAP and the angiographic results are summarised in Table 3.
All of the patients agreed to participation in the study andTable 1 – Demographics and list of medication on
admission.
A (control) B (SAP) p
Patients, n 22 22
Men/woman, n (%) 9 (41)/13 (59) 16 (73)/6 (27) 0.0666
Age, years7SD 64,0712.6 64,779.3 0.8601
Risk factors
Hypertension, n (%) 11 (50) 21 (95) 0.0015
Smoking, n (%) 3 (14) 7 (32) 0.2806
Dyslipidaemia, n (%) 13 (59) 18 (82) 0.1854
Diabetes, n (%) 6 (27) 9 (41) 0.5256
Medication on admission
Beta blockers, n (%) 6 (27) 14 (64) 0.0329
Aspirin, n (%) 9 (41) 16 (73) 0.0666
ADP blockers, n (%) 2 (9) 5 (23) 0.4121
Statins, n (%) 12 (55) 18 (82) 0.5365
Nitrates, n (%) 1 (5) 5 (23) 0.1853
ACE inhibitors, n (%) 5 (23) 14 (64) 0.0139
ARB, n (%) 2 (9) 3 (14) 1.0000
Ca blockers, n (%) 4 (18) 5 (23) 1.0000
Coumadin, n (%) 2 (9) 2 (9) 1.0000
SD—standard deviation; dyslipidaemia—(statin use or increased
cholesterol levels ); ADP—adenosine diphosphate; ACE—angioten-
sin converting enzyme; ARB—angiotensin receptor blockers;
Ca—calcium.
Table 2 – Final diagnosis in the control group.
N
Atypical chest pain 18
Cardiomyopathy 2
Valve disease 2signed a consent approved by the Ethics Committee of the
University Hospital Motol.
2.1. Blood sampling
Blood was collected by venipuncture into tubes coated with
EDTA. Plasma was obtained by centrifugation (15 min, 3000g)
of blood samples. The supernatant was centrifuged once
more under the same conditions. Subsequently, the obtained
(clear) plasma was transferred to polypropylene Eppendorf
tubes and stored at 70 1C until used.
2.2. Plasma depletion
Plasma depletion is based on the removal of abundant
proteins, which constitute more than 90% of protein mass
in plasma. The depletion is necessary to uncover small
proteins with low plasma concentrations. In our study, six
proteins were depleted (albumin, IgG, a1-antitrypsin, IgA,
transferrin and haptoglobin).
Plasma samples were centrifuged (5 min, 12,000g), diluted
1:4 in depletion buffer (Agilent, CA, USA) and filtered using
0.22 mm Spin filters (Agilent Technologies, USA) for 1 min by
centrifugation at 12,000g. MARS Hu-6 4.6 mm100 mm
columns (Agilent Technologies, CA, USA) were used to
remove the six most abundant proteins (albumin, IgG, a1-
antitrypsin, IgA, transferrin and haptoglobin). Spin Concen-
trators 5K MWCO (Agilent Technologies, CA, USA) were used
to desalinate and concentrate the samples (3000g, 20 1C).
MilliQ water (4 ml) was added to concentrated samples, and
the desalinating–concentrating step was repeated three
times. Finally, desalinated and concentrated samples were
vacuum dried, frozen rapidly and stored at 70 1C.
2.3. Two-dimensional electrophoresis (2D SDS-PAGE)
Two-dimensional electrophoresis was performed as described
previously [4]. Briefly, the samples were resuspended and
centrifuged at 37,500g at 20 1C for an hour. Following IEF, strips
were equilibrated for 20 min in DTT followed by equilibration
in iodoacetamide. Proteins were separated in the second
dimension on SDS-PAGE. Following electrophoresis, the gels
were stained with colloidal Coomassie blue stain (17% w/v
ammonium sulphate, 1.8% H3PO4, 35% v/v methanol and
Fig. 1 – Five different spots on 2D SDS-PAGE.
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acetic acid.
2.4. Image analysis
Scanned images (16-bit grayscale) were processed with Progen-
esis SameSpots software (Nonlinear Dynamics, UK). Both manual
and automatic alignments were used to align the images.
Normalised volumes of the spots, instead of spot intensity, were
used in the statistical analysis, and only spots that fulfilled
statistical criteria (ANOVA po0.05 and foldZ1.5) were accepted
for protein identification. The fold change is a value related to the
average amount of all proteins in the spot calculated as a ratio
normalised to the control. The fold change value shown in the
spot list is calculated from the mean normalised volumes of
respective spots in sample and control gels.
2.5. In-gel digest
Selected spots were excised from the gel and destained in a 1:1
ratio of 100 mM NH4HCO3 and acetonitrile. Destained gel
pieces were dehydrated with acetonitrile, rehydrated with
100 mM NH4HCO3 and then dehydrated with acetonitrile once
again. Finally, vacuum dried gel pieces were rehydrated in
trypsin solution (12.5 ng/ml of trypsin in 25 mM NH4HCO3), and
then trypsin digestion was performed at 37 1C for 16 h. Next, a
solution of 50% acetonitrile/0.1% formic acid was added to the
gel pieces, and peptides were extracted by agitation for
15 min. The supernatant was recovered, and the extraction
step was repeated once again. The supernatants were pooled,
dried and dissolved in 2% acetonitrile/0.1% formic acid.
2.6. Liquid chromatography (LC) and mass spectrometric
analysis (MS)
An ion-trap mass spectrometer [MS HCTultra (Bruker Daltonik,
Germany) with nanoelectrospray ionisation coupled to the
nanoLC system UltiMate 3000 (Dionex Corporation, CA, USA)]
was used to perform mass spectrometric analyses. Tryptic
peptides were desalted on a 300 mm ID/5 mm-length C18
PepMap 100 precolumn (LC Packings, CA, USA) and separated
on a 75 mm ID/15 cm-length C18 PepMap 100 analytical column
(LC Packings, CA, USA). A gradient of acetonitrile was used to
elute peptides (0–20% B in 2 min, 20–50% B in 15 min; mobile
phase A: 2% ACN/0.1% formic acid, mobile phase B: 80%
ACN/0.1% formic acid) at a flow rate of 300 nl/min. The nanoLC
system was connected to MS using a PicoTip needle (New
Objective, MA, USA) with an applied voltage of 1500 V. The flow
of the dry gas was 10 l/min with a dry temperature of 160 1C.
The ‘‘Standard Enhanced’’ positive scan mode for collision
induced dissociation (CID) data acquisition was used. The scan
ranges were 300–1500m/z and 100–2500m/z for MS and MS(2),
respectively. Three precursor ions were selected during one
autoMS(2) cycle, and active exclusion (0.35 min, singly charged
ions) was used. EsquireControl v6.2 software was used for data
acquisition. DataAnalysis v4.0 was used for data processing,
and BioTools v3.2 (all software above, Bruker Daltonik,
Germany) together with MASCOT (Matrix Science, UK) were
used for database searching (SWISS-PROT 57.0). The following
database search parameters were utilised: taxonomy wasrestricted to Homo sapiens, carbamidomethyl (C) was selected
as a fixed modification and oxidation (M) as a variable
modification, the number of missed cleavages was restricted
to 1, mass was monoisotopic and the mass tolerance was 0.1%
for MS and 0.5 Da for MS/MS.3. Results
Altogether, 44 2D SDS-PAGE gels were processed throughout
the experiment. Scanned gel images were divided into two
individual subgroups: (A) controls (22 gels) and (B) stable angina
pectoris (22 gels). Progenesis SameSpots software was utilised
to process the image analysis. Using both manual and
automatic image alignment, applying pre-filtering (edge and
area exclusion, minimal spot area or normalised volume) and
specific criteria (ANOVA po0.05, minimum fold change of 1.5),
five spots were detected that significantly differed in their
normalised volumes (Fig. 1). Four proteins in these five spots
were successfully identified by nanoscale liquid chromatogra-
phy/tandem mass spectrometry (nanoLC-MS/MS). At least two
protein-unique peptides (fulfilling a minimal MASCOT score)
were necessary for the identification of a protein. The list of
spots, including protein identification with ANOVA p-value, fold
difference, sequence coverage protein and accession number
(SWISS-PROT 57.0), are summarised in Table 4.
Increased or decreased normalised volumes of protein
mass are due to changes in amount of protein or due to
posttranslational modifications. Compared to controls, the
stable angina pectoris subgroup showed increased normal-
ised volumes of two spots containing the Serum Amyloid A
and Fibrinogen chains. Decreased normalised volumes were
identified in three spots containing Apoliprotein-A1 and
pigment epithelium derived factor (PEDF).4. Discussion
Humans have 30,000–40,000 genes, which is only approxi-
mately twice the number of less complex organisms such as
Table 4 – List of identified proteins.
AN identifikace P Fold SC %
P02647 Apolipoprotein A-I 0.0035 1.6 50
P02647 Apolipoprotein A-I 0.0134 1.8 47
P02735 Serum amyloid A protein 0.0304 1.9 36
P36955 Pigment epithelium-derived factor 0.0099 1.5 36
P02679 Fibrinogen gamma chain 0.0001 1.6 27
The list of spots including protein identification with ANOVA p-value, fold difference (when compared with the control group), sc: sequence
coverage of protein (%).
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proteins due to alternative splicing of transcripts and protein
post-translational changes. Thus, although the genome is
stable and gives information about the potential of an
organism, the proteome is dynamic and reflects the biological
processes that are taking place in that organism. Both
approaches are complementary and, along with transcrip-
tomics and metabolomics (which study the transcripts and
the metabolites, respectively), integrate the so-called ‘‘omic’’
sciences [6].
Proteomic analysis can utilise almost any tissue. The
analysis of the atherosclerotic plaques has identified osteo-
pontin as a potential biomarker of poor prognosis. During
three years of follow up, it was confirmed that a high
expression of osteopontin was associated with a higher
incidence of cardiovascular events [7].
Proteomic analysis of whole blood is methodologically
easier. The proteome of the blood cells or plasma can be
investigated. The analysis of the blood cells is more difficult
because of the necessity of the isolation of the cells and
extraction of the proteins. These investigations are also
difficult because of the critical time delay (no more than four
hours) to process samples. Plasma samples differ in that
frozen samples can be stored for a long time.
During the analysis of circulating monocytes sampled from
patients with acute coronary syndrome without ST eleva-
tions, 17 proteins with altered expression were altogether
identified when compared with patients with stable angina
pectoris. There were decreased antiatherogenic proteins such
as paraoxonase or HSP 70 and anti-inflammatory proteins
such as protein disulphide isomerase. Increased expression
was associated with cathepsin D and enolasis I [8].
Proteomic analysis faces many limitations. As mentioned
in the methods section, six proteins (albumin, IgG, a1-
antitprypsin, IgA, transferrin and haptoglobin) represent
more than 90% of the protein plasma mass. The depletion
process separates these proteins as well as proteins that are
associated, mainly to albumin. However, without this deple-
tion, further analysis is impossible. Another limitation is the
sensitivity of the method. Using a proteomic approach in
plasma, only approximately 3000 genes are now recognised
[9,10], much less than the hypothetically anticipated 900,000.
Proteomic analysis of patients with ischaemic stroke
confirmed high levels of haptoglobin and serum amyloid A
in the subgroup of patients with atherothrombotic events in
comparison with embolic events [11]. In patients with acute
coronary syndrome, studies show decreased levels of differ-ent isoforms of alfa1-antitrypsin or apolipoprotein A-1 and
increased levels of fibrinogen chains and heavy chain
gammaglobulins [12].
In our research, we compared two subgroups of patients:
(1) with stable angina pectoris and (2) without documented
significant coronary artery disease. A subgroup of patients
without coronary artery disease served as controls. The
results of proteomic analysis found only very discrete
changes in the spectrum of proteins, which correlates well
with clinical observations of small differences in patients
with stable ischaemic heart disease compared to the general
population. The level of the disease documented by severity
of angina seems not to influence the spectrum of molecules
because increasing angina is here associated with the severity
and extension of the atherosclerotic lesions, more then with
superimposed thrombosis, which causes the acute coronary
syndrome and where molecular spectrum will be due to
thrombotic process different [12]. In the plasma of patients
with stable angina pectoris, our results show increased levels
of serum amyloid A and gamma chains of fibrinogen.
Decreased levels of apolipoprotein A1 and pigment epithe-
lium derived factor (PEDF) were also found.
Serum amyloid A protein is a member of the family of
inflammatory proteins. C reactive protein belongs to the same
family and is currently widely used as an indicator for
increased risk of cardiovascular events [13,14]. Serum amyloid
A protein was reported to have a more rapid response and
different kinetics. Its addition to the C reactive protein level
indicators increases the predictive value for the risk of death,
myocardial (re)infarction and the need for target-vessel
revascularisation in 30 day, compared with C reactive protein
levels alone [15,16]. Increased levels of C reactive protein and
serum amyloid A protein were the independent predictors of
poor prognosis in severe unstable angina patients at admis-
sion [17].
Besides its role in inflammation, fibrinogen plays an
important role in the coagulation cascade, and it is estab-
lished that increased C reactive protein and fibrinogen levels
are predictors of poor long term prognosis [18,19]. Both of
these findings correlate well with current established patho-
physiology of atherosclerosis.
The role of apolipoprotein A-1 has been widely investigated.
Apolipoprotein A-1 is a major apoliprotein of HDL cholesterol
and is protective against atherosclerosis through several
mechanisms including the ability to mediate reverse cholesterol
transfer [20]. In the setting of coronary artery disease, dysfunc-
tional HDL cholesterol has been found to be caused by oxidative
C O R E T VA S A 54 ( 2012 ) e22 –e26e26damage [21]. The decreased presence of apoliprotein A-1 found
in the subgroup of acute coronary syndrome patients correlates
well with the lipid theory of atherosclerosis.
PEDF is involved in pathogenesis of diabetic proliferative
retinopathy. Because of the fact that atherosclerosis is a
proliferative and inflammatory disease, and PEDF blocks
reactive oxygen radicals, one can assume the important role
also in the atherosclerosis [22].
Our results suggest that the subgroup without clinical
manifestation of atherosclerosis and the subgroup with
chronic ischaemic heart disease are, from the point of
proteomic view, identical. This corresponds with the view of
atherosclerosis as a systemic disease where one can suppose
some degree of atherosclerotic disease by the age of 50 in
persons exposed to risk factors. Their clinical characteristics
correspond only with the severity of the disease and not with
presence or absence of atherosclerosis.
In this study, the small numbers of patients has so far been
the limitation of all proteomic studies due to methodological
complexity and expense.5. Conclusions
Our results show the availability and utility of proteomic
analysis as a method for prognosis and its shift from bench to
bedside, which brings new insight into both the pathophy-
siology and clinical manifestation of atherosclerosis.Acknowledgements
This study was supported by Grants NS10633-3/2009,
MZOFNM2005 and MZ 02373601 from the Ministry of Health,
Czech Republic; by Grant KAN200670701 from the Academy of
Sciences, Czech Republic; by Baxter, Czech Republic.
R E F E R E N C E S
[1] D.T. Miller, P.M. Ridker, P. Libby, D.J. Kwiatowski, Atheroslerosis—
the path from genomics to therapeutics, Journal of the
American College of Cardiology 49 (2007) 1589–1599.
[2] A.P. Bijnens, E. Lutgens, T. Ayoubi, J. Kuiper, A.J. Horrevoets,
M.J. Daemen, Genome-wide expression studies of athero-
sclerosis: critical issues in methodology, analysis, interpreta-
tion of transcriptomics data, Arteriosclerosis Thrombosis
and Vascular Biology 26 (2006) 1226–1235.
[3] T.T. Tuomisto, B.R. Binder, S. Yla-Herttuala, Genetics, geno-
mics and proteomics in atherosclerosis research, Annals of
Medicine 37 (2005) 323–332.
[4] P. Majek, Z. Reicheltova, J. Stikarov a, J. Suttnar, A. Sobotkova,
J.E. Dyr, Proteome changes in platelets activated by arachidonic
acid, collagen and thrombin, Proteome Science 8 (2010) 56.
[5] J.C. Venter, M.D. Adams, E.W. Myers, et al., The sequence of
the human genome, Science 291 (2001) 1304–1351.
[6] J. Tunˇo´n, J.L. Martı´n-Ventura, L.M. Blanco-Colio, O. Lorenzo,
J.A. Lo´pez, J. Egido, Proteomic strategies in the search of newbiomarkers in atherothrombosis, Journal of the American
College of Cardiology 55 (2010) 2009–2016.
[7] F.L. Moll, De Kleijn, W.E. Hellings, et al., Local atherosclerotic
plaques are a source of prognostic biomarkers for adverse
cardiovascular events, Arteriosclerosis Thrombosis and Vas-
cular Biology 30 (2010) 612–619.
[8] M.G. Barderas, J. Tunˇo´n, V.M. Dard e, et al., Circulating human
monocytes in the acute coronary syndrome express a
characteristic proteomic profile, Journal of Proteome
Research 6 (2007) 876–886.
[9] L. Anderson, Candidate-based proteomics in the search for
biomarkers of cardiovascular disease, Journal of Physiology
563 (2005) 23–60.
[10] P. Ping, T.M. Vondriska, C.J. Creighton, et al., A functional
annotation of subproteomes in human plasma, Proteomics 5
(2005) 3506–3519.
[11] D. Brea, T. Sobrino, M. Blanco, et al., Usefulness of haltoglobin
and serum amyloid A proteins as biomarkers for athero-
thrombotic ischemic stroke diagnosis confirmation, Athero-
sclerosis 205 (2009) 561–567.
[12] P.J. Mateos-C aceres, A. Garcı´a-M endez, A. Lo´pez Farr e, et al.,
Proteomic analysis of plasma from patients during an acute
coronary syndrome, Journal of the American College of
Cardiology 44 (2004) 1578–1583.
[13] I. Ikonomidis, J. Lekakis, I. Revela, F. Andreotti, P. Nihoyan-
nopoulos, Increased circulating C-reactive protein and
macrophage-colony stimulating factor are complementary
predictors of long-term outcome in patients with chronic
coronary artery disease, European Heart Journal 26 (2005)
1618–1624.
[14] S.G. Foussas, M.N. Zairis, A.G. Lyras, et al., Early prognostic
usefulness of C-reactive protein added to the thrombolysis in
myocardial infarction risk score in acute coronary syn-
dromes, American Journal of Cardiology 96 (2005) 533–537.
[15] M. Kosuge, T. Ebina, T. Ishikawa, et al., Serum Amyloid A is a
better predictor of clinical outcomes than C-reactive protein
in non-ST-Segment elevation acute coronary syndromes,
Circulation Journal 71 (2007) 186–190.
[16] A.M. Svensson, G.R. Whiteley, P.W. Callas, E.G. Bovill, SELDI-
TOF plasma profiles distinguish individuals in a protein
C-deficient family with thrombotic episodes occuring before
age 40, Thrombosis and Haemostasis 96 (2006) 725–730.
[17] G. Liuzzo, L.M. Biasucci, J.R. Gallimore, et al., The prognostic
value of C-reactive protein and serum amyloid a protein in
severe unstable angina, New England Journal of Medicine 331
(1994) 417–424.
[18] Y. Shi, Y. Wu, C. Bian, W. Zhang, J. Yang, G. Xu, Predictive value of
plasma fibrinogen levels in patients admitted for acute coronary
syndrome, Texas Heart Institute Journal 37 (2010) 178–183.
[19] T. Riedel, J. Suttnar, E. Brynda, M. Houska, L. Medved, J.E. Dyr,
A. Fibrinopeptides, and B release in the process of surface
fibrin formation, Blood 117 (2011) 1700–1706.
[20] J.D. Smith, Apoliprotein A-1 and its mimetics for the
treatment of atherosclerosis, Current Opinion in Investiga-
tional Drugs 11 (2010) 989–996.
[21] J.W. Heinecke, The HDL-proteome: a marker and perhaps a
mediator of coronary artery disease, The Journal of Lipid
Research 50(S) (2009) 167–171.
[22] N. Tahara, S.I. Yamagishi, A. Tahara, et al., Serum level of
pigment epithelium-derived factor is a marker of athero-
sclerosis in humans, Atherosclerosis, 2011, Epub ahead
of print.
